Acinetobacter baumannii

Overview

Acinetobacter baumannii is a Gram-negative, opportunistic bacterial pathogen of major clinical importance, particularly in healthcare settings. It is best known for causing difficult-to-treat infections in vulnerable patients, including wound infections, respiratory infections, and post-surgical infections, and for its ability to persist in the hospital environment and acquire multidrug resistance. A major reason for its clinical significance is its capacity to develop resistance to multiple antibiotic classes, including β-lactams and carbapenems, which has made carbapenem-resistant A. baumannii (CRAB) a global therapeutic concern.

Biologically, A. baumannii is notable for intrinsic and acquired resistance mechanisms, including AmpC-type β-lactamases such as the Acinetobacter-derived cephalosporinases (ADCs), which can be overexpressed through insertion sequence-driven mechanisms. Its outer membrane biology, biofilm-forming potential, and adaptability under stress contribute to persistence and pathogenicity. Because of these features, A. baumannii is frequently used as a target organism in studies of new antimicrobials, diagnostic assays, vaccines, and host-directed or materials-based infection-control strategies.

Focus of Latest Publications

Recent studies have continued to position Acinetobacter baumannii as a key target in antimicrobial discovery, rapid diagnostics, and vaccine development. Several reports focused on identifying compounds or materials with direct antibacterial activity against the organism. For example, phenothiazine dye-loaded chitosan cryogels were shown to produce clear bactericidal effects against A. baumannii in disk diffusion testing, with an inhibition zone reported at 31.2 ± 0.41 mm. Similarly, benzimidazole-based derivatives were screened against A. baumannii alongside Enterococcus faecalis, Staphylococcus aureus, Providencia stuartii, and Candida albicans, reflecting ongoing interest in broad-spectrum antimicrobial scaffolds. Another study found that a multivalent glycopolymer, poly2DG, inhibited MDR pathogens including A. baumannii with very low MIC50 values, and a separate investigation reported that itaconate at 29.13 mM completely inhibited growth of A. baumannii in carbon-rich liquid culture.

Natural products and computationally guided discovery also featured prominently. Anagallis foemina-derived terpenoids were evaluated experimentally and computationally against carbapenem-resistant A. baumannii, in the context of rising carbapenem resistance worldwide. Likewise, elfamycin-class inhibitors discovered from Antarctic-derived Streptomyces sp. A3-7 were reported as active against CRAB, underscoring the continued search for novel antibacterial chemotypes. In another study, Cichorium intybus extract was assessed against multidrug-resistant bacterial isolates, including A. baumannii, using microbiological characterization and phytochemical profiling. These studies collectively reinforce the organism’s role as a benchmark pathogen for testing new anti-infective strategies.

Acinetobacter baumannii was also central to vaccine and immunoprophylaxis research. A biodegradable polymeric nanoparticle vaccine was reported to protect mice from lethal A. baumannii challenge, with pre-immunized animals achieving 100% survival in the challenge experiment. In a related direction, mucosal vaccination in mice was reported to protect against diverse respiratory threats, including A. baumannii, suggesting that broader mucosal immune strategies may confer cross-protection against bacterial pathogens. Another study examined A. baumannii-derived outer membrane vesicles (OMVs) conjugated with Vaccinium myrtillus extract in pancreatic cancer cells, indicating that bacterial components can also be repurposed in noninfectious biomedical contexts, here as a platform for redox-mediated signaling studies in PANC-1 cells.

Diagnostic innovation has also been a major theme. An extraction-free HLPCR-Cas12a assay was developed for ultra-sensitive and rapid detection of A. baumannii and Klebsiella pneumoniae after craniotomy, reflecting the clinical need for fast identification of drug-resistant postoperative pathogens. This work aligns with the broader use of HLPCR-CRISPR/Cas12a, Cas12a/crRNA complex-based detection, and qPCR-adjacent molecular diagnostics in infection control. In addition, studies of clinical isolates identified A. baumannii among common drug-resistant pathogens recovered from patient samples, emphasizing its continued prevalence in healthcare-associated infections.

Mechanistic research has continued to clarify why A. baumannii is so difficult to treat. One study focused on ADC β-lactamases, showing that a Val292 substitution combined with an alanine duplication in the Ω loop can reduce susceptibility to advanced β-lactam agents, including cefiderocol. This finding highlights the importance of β-lactamase structure in resistance evolution and supports the view that intrinsic Acinetobacter-derived cephalosporinases are central to the organism’s drug resistance phenotype. Another report described BV100 (rifabutin for infusion), an intravenous formulation being developed for serious or life-threatening infections due to carbapenem-resistant A. baumannii in patients with limited treatment options, and its evaluation in a Phase 1 study for pharmacokinetics, safety, and tolerability in healthy volunteers.

Across these studies, A. baumannii remains a model organism for urgent translational research because it sits at the intersection of antimicrobial resistance, rapid diagnostics, vaccine design, and host-pathogen interaction studies. Its repeated appearance alongside Staphylococcus aureus, Klebsiella pneumoniae, Pseudomonas aeruginosa, Candida albicans, and Aspergillus fumigatus reflects its role in broad-spectrum screening platforms and mixed-pathogen clinical contexts.

Key Publications

• Jun Phenothiazine dye-loaded chitosan cryogels as multifunctional antibacterial wound dressings. (Scientific reports, 2026, PMID 42324341): "In particular, the bactericidal effects of cryogels (CSC2 and CSC3) were demonstrated against Escherichia coli (33.5±0.1 mm), Pseudomonas aeruginosa (32.4±0.28 mm), Acinetobacter baumannii (31.2±0.41 mm), Staphylococcus aureus (29.2±0.28 mm), Streptococcus pyogenes (28.7±0.35 mm), and Enterococcus faecalis (27.5±0.81 mm)."
• Jun Design and synthesis of benzimidazole-based derivatives with antimicrobial activity: mechanistic insights into ROS-mediated oxidative damage, hemolytic assessment, and molecular docking studies. (Bioorganic chemistry, 2026, PMID 41831427): "All compounds were evaluated for antimicrobial activity against Gram-positive bacteria (Enterococcus faecalis and Staphylococcus aureus), Gram-negative bacteria (Acinetobacter baumannii and Providencia stuartii), and the fungal strain Candida albicans."
• May Combating multidrug-resistant bacteria and associated virulence factors using Cichorium intybus extract: integrated microbiological characterization, phytochemical profiling, cytotoxicity assessment, and mechanistic insights. (Scientific reports, 2026, PMID 42191794): "A total of 75 bacterial isolates were identified using morphology, biochemical testing, and VITEK®2 (96-98% accuracy), including Klebsiella pneumoniae (56%), Escherichia coli (24%), and Acinetobacter baumannii (20%) (χ2(2)=17.52, p<0.001)."
• May Mucosal vaccination in mice provides protection from diverse respiratory threats. (Science (New York, N.Y.), 2026, PMID 41712698): "...protected mice from other viruses (SARS-CoV-2, SARS, SHC014 coronavirus), bacteria (Acinetobacter baumannii), and allergens."
• May A Val292 substitution combined with an alanine duplication (ADUP) in the Ω loop of ADC β-lactamase confers reduced susceptibility to advanced β-lactam agents, including cefiderocol. (mBio, 2026, PMID 41949313): "Intrinsic Acinetobacter-derived cephalosporinases (ADCs) in Acinetobacter baumannii are AmpC-type β-lactamases that confer resistance to β-lactam agents, typically through insertion sequence (IS) element-driven overexpression."
• May Multivalent Glycopolymer Design Unlocks Antimicrobial Activity of 2-Deoxyglucose. (Angewandte Chemie (International ed. in English), 2026, PMID 41957856): "Significantly, poly2DG exhibits broad-spectrum bacterial inhibition, including against MDR methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Acinetobacter baumannii, with MIC50 values as low as 0.2 μg/mL."
• May A biodegradable polymeric nanoparticle vaccine for combating Acinetobacter baumannii infection. (Biomaterials science, 2026, PMID 41969157): "In a challenge experiment, mice pre-immunized with NP-VAC achieved a 100% survival rate following a lethal dose of Acinetobacter baumannii infection."
• May Redox-mediated activation of PI3K/PTEN pathways by A. baumannii OMV-V. myrtillus conjugate in pancreatic cancer cells. (Archives of microbiology, 2026, PMID 42101625): "This study aimed to evaluate the anticancer potential of Acinetobacter baumannii-derived outer membrane vesicles (OMVs) conjugated with Vaccinium myrtillus extract, a low-toxicity natural compound, against pancreatic cancer cells."
• May Discovery of elfamycin-class inhibitors combating carbapenem-resistant Acinetobacter baumannii from the Antarctic-derived Streptomyces sp. A3-7. (Bioorganic chemistry, 2026, PMID 41671746): "Carbapenem-resistant Acinetobacter baumannii (CRAB) poses a critical global health threat."
• May Ligand-Based Design of Novel Thiazole-Quinazolinone Hybrids with Dual Antimicrobial and Anti-Virulence Activity Targeting Staphylococcal Sortase A. (Bioorganic & medicinal chemistry, 2026, PMID 41650554): "...evaluated for their antimicrobial activity against six clinically relevant pathogens (Staphylococcus aureus, Bacillus subtilis, Acinetobacter baumannii, Klebsiella pneumoniae, Candida albicans, and Aspergillus fumigatus)."